Market Overview

Deutsche Bank Reiterates Buy on Vertex Pharmaceuticals Following Press Release

Share:
Related VRTX
JPMorgan, Canaccord Confident That Vertex's CF Drug Will Get FDA Approval
Vertex Shares Rally As FDA Panel Backs Orkambi; HC Wainwright Analyst Offers Thoughts
5 Drugs That Could Be Summer Blockbusters (Investor's Business Daily)

Following the press release issued earlier Tuesday morning by Vertex Pharmaceuticals (NASDAQ: VRTX), Deutsche Bank analyst, Robyn Karnauskas reiterated the firm's Buy rating and $103.00 price target for Vertex shares.

Karnauskas wrote, "Bottom line: We believe that this is the first step in Vertex platform treating entire cystic fibrosis population." Karnauskas based this on the belief that doctors will use the regimen for the high unmet need among the cystic fibrosis community for a viable treatment.

For a more detailed look into the press release see Why Is Vertex Pharmaceuticals Up More Than 50 Percent?

Latest Ratings for VRTX

DateFirmActionFromTo
Apr 2015CitigroupMaintainsBuy
Apr 2015OppenheimerAssumesPerform
Apr 2015Canaccord GenuityInitiates Coverage onBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (VRTX)

Around the Web, We're Loving...

Get Benzinga's Newsletters